Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marimastat in minimal disease stage III NSCLC
NCT00002911Phase 3Completed
- Sponsor
- ILEX Oncology, Inc.
- Start
- Dec 1996
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Marimastat with Placebo (2 arms). Primary endpoint: Overall Survival. Started Dec 1996; status: completed.
02
Drugs
marimastat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00002911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002911.